Memphasys Ltd (MEM)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Memphasys Ltd (MEM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013364
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Memphasys Ltd (Memphasys), formerly Nusep Holdings Ltd is a life science company that develops and sells pre-cast electrophoresis gels, separations equipment and consumables, analytical software, and other biological products. The company offers gels which include tris glycine, and tris hepes. It offers buffers, stains and drying solutions. Memphasys offers proteomesep, which is a bench-top instrument capable of simultaneous charge and size separation of complex protein mixtures. The company also offers LA reagents and general reagents. It caters to therapeutic plasma, IVF clinical, and research consumables markets. The company operates in Australia, Singapore and the US. Memphasys is headquartered in Homebush West, New South Wales, Australia.

Memphasys Ltd (MEM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Memphasys Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Memphasys Ltd, Medical Devices Deals, 2011 to YTD 2017 8
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Memphasys Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
PrIME Biologics To Raise US$15.8 Million In Private Equity Financing 10
Equity Offering 11
Memphasys Plans to Raise USD0.3 Million in Rights Offering of Shares 11
Memphasys Plans to Raise USD0.9 Million in Private Placement of Shares 12
Memphasys Raises Funds in Public Offering of Shares 13
NuSep to Raise Funds through Share Purchase Plan 14
NuSep Completes Private Placement Of Shares For US$1 Million 15
NuSep Completes Rights Offering Of Shares For US$1.7 Million 16
NuSep Completes Public Offering Of Common Stock For US$1.9 Million 17
NuSep Completes Private Placement For US$0.99 Million 19
Debt Offering 21
Memphasys Plans to Raise USD0.2 Million in Public Offering of Notes Due 2017 21
Asset Transactions 22
Premier Biosoft Acquires ProteoIQ Business From NuSep 22
Acquisition 23
A-Bio Pharma To Acquire 10% Stake In PrIME Biologics From NuSep For US$4.8 Million 23
Memphasys Ltd – Key Competitors 24
Memphasys Ltd – Key Employees 25
Memphasys Ltd – Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Memphasys Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Memphasys Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Memphasys Ltd, Medical Devices Deals, 2011 to YTD 2017 8
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
PrIME Biologics To Raise US$15.8 Million In Private Equity Financing 10
Memphasys Plans to Raise USD0.3 Million in Rights Offering of Shares 11
Memphasys Plans to Raise USD0.9 Million in Private Placement of Shares 12
Memphasys Raises Funds in Public Offering of Shares 13
NuSep to Raise Funds through Share Purchase Plan 14
NuSep Completes Private Placement Of Shares For US$1 Million 15
NuSep Completes Rights Offering Of Shares For US$1.7 Million 16
NuSep Completes Public Offering Of Common Stock For US$1.9 Million 17
NuSep Completes Private Placement For US$0.99 Million 19
Memphasys Plans to Raise USD0.2 Million in Public Offering of Notes Due 2017 21
Premier Biosoft Acquires ProteoIQ Business From NuSep 22
A-Bio Pharma To Acquire 10% Stake In PrIME Biologics From NuSep For US$4.8 Million 23
Memphasys Ltd, Key Competitors 24
Memphasys Ltd, Key Employees 25

★海外企業調査レポート[Memphasys Ltd (MEM)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Syngene International Ltd (SYNGENE):製薬・医療:M&Aディール及び事業提携情報
    Summary Syngene International Ltd (Syngene), a subsidiary of Biocon Ltd, is a clinical research and manufacturing organisation. The organisation offers research, development and manufacturing programs. It provides discovery chemistry, discovery biology, large molecule development, safety assessment, …
  • Natural Alternatives International Inc (NAII):企業の財務・戦略的SWOT分析
    Summary Natural Alternatives International Inc (NAI) is a formulator and manufacturer of customized nutritional supplements. It manufactures and distributes the only patented beta-alanine supplement CarnoSyn. It offers services such as science-based product formulation, raw material acquisition and …
  • Stockmann plc (STCBV):企業の財務・戦略的SWOT分析
    Stockmann plc (STCBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Teva Pharmaceuticals USA Inc-製薬・医療分野:企業M&A・提携分析
    Summary Teva Pharmaceuticals USA Inc (Teva Pharmaceuticals), formerly Lemmon Pharmacal Company, a subsidiary of Teva Pharmaceutical Industries Ltd, is a developer and manufacturer of pharmaceutical ingredients. The company’s products include antiulcer agents and acid suppressants, antiviral capsules …
  • Progenics Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Progenics Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Progenics Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Freehold Royalties Ltd (FRU):企業の財務・戦略的SWOT分析
    Summary Freehold Royalties Ltd (Freehold Royalties), formerly Freehold Royalty Trust is an oil and gas company that offers oil and gas operation and financial performance. Its oil and gas assets generate income from natural gas, crude oil, natural gas liquids and potash deposits. It provides horizon …
  • Utah Medical Products Inc (UTMD):企業の財務・戦略的SWOT分析
    Summary Utah Medical Products Inc (Utah Medical) is a medical device company that offers disposable and reusable products. The company offers blood pressure monitoring and blood management, gynecology, perinatology, urology and electrosurgery, respiratory and OEM products. Its blood pressure monitor …
  • ABF Ingredients Ltd:企業の戦略・SWOT・財務情報
    ABF Ingredients Ltd - Strategy, SWOT and Corporate Finance Report Summary ABF Ingredients Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Toyobo Co., Ltd.:企業の戦略・SWOT・財務分析
    Toyobo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toyobo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Aevi Genomic Medicine Inc (GNMX):企業の財務・戦略的SWOT分析
    Summary Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The company provides pipeline products such as AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glut …
  • Wilson Therapeutics AB (WTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Wilson Therapeutics AB (Wilson Therapeutics), a subsidiary of Alexion Pharma Nordics AB, is a biopharmaceutical company that develops novel therapies for patients with rare copper-mediated disorders. The company’s lead product includes WTX101 is a copper-protein-binding agent, which is used …
  • Water Intelligence PLC (WATR):企業の財務・戦略的SWOT分析
    Summary Water Intelligence plc (Water Intelligence) formerly Qonnectis Plc, is a clean technology company that offers environmental and technology services. The company offers services such as finding, detecting, and remediating water leaks services. It monitors and protects water infrastructure and …
  • Northbridge Financial Corporation:企業の戦略的SWOT分析
    Northbridge Financial Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Misawa Homes Co., Ltd.:戦略・SWOT・企業財務分析
    Misawa Homes Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Misawa Homes Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Stantec Inc:企業のM&A・事業提携・投資動向
    Stantec Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Stantec Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Mount Tam Biotechnologies Inc (MNTM):企業の財務・戦略的SWOT分析
    Summary Mount Tam Biotechnologies Inc (Mount Tam Biotechnologies), a subsidiary of TabacaleraYsidron Inc is a provider of pharmaceutical products that offers development and commercialization of medical compounds for autoimmune diseases. The company’s lead product candidate TAM-0, a rapamycin analog …
  • ARC Resources Ltd (ARX):石油・ガス:M&Aディール及び事業提携情報
    Summary ARC Resources Ltd (ARC) is an energy company, which carries out exploration, development and production of conventional crude oil and natural gas reserves. Its produces light and medium crude oil, heavy oil, tight oil, condensate, natural gas and natural gas liquids. The company’s operations …
  • Public Broadcasting Service:企業の戦略・SWOT・財務情報
    Public Broadcasting Service - Strategy, SWOT and Corporate Finance Report Summary Public Broadcasting Service - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Ascent Solar Technologies Inc (ASTI)-エネルギー分野:企業M&A・提携分析
    Summary Ascent Solar Technologies, Inc. (Ascent solar) is a developer and manufacturer of thin-film photovoltaic modules using substrate materials. It develops products by using thin-film copper-indium-gallium- diselenide (CIGS) photovoltaic technology. The product portfolio of the company includes …
  • Enel SpA (ENEL)-石油・ガス分野:企業M&A・提携分析
    Summary Enel S.p.A. (Enel) is an energy group that produces, distributes and trades electricity and natural gas. The group generates electricity using diverse sources of energy such as nuclear, renewables, oil and gas turbine, coal and gas combined cycle. It also focuses on digitizing electricity gr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆